Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Open Access
- 21 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 13 (1), 1-16
- https://doi.org/10.1186/s13045-020-00874-6
Abstract
Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is usually a platinum drug, such as cisplatin or carboplatin, combined with a taxane. However, despite surgical removal of the tumor and initial high response rates to first-line chemotherapy, around 80% of women will develop cancer recurrence. Effective strategies, including chemotherapy and new research models, are necessary to improve the prognosis. The replication stress response (RSR) is characteristic of the development of tumors, including ovarian cancer. Hence, RSR pathway and DNA repair proteins have emerged as a new area for anticancer drug development. Although clinical trials have shown poly (ADP-ribose) polymerase inhibitors (PARPi) response rates of around 40% in women who carry a mutation in the BRCA1/2 genes, PARPi is responsible for tumor suppression, but not for complete tumor regression. Recent reports suggest that cells with impaired homologous recombination (HR) activities due to mutations in TP53 gene or specific DNA repair proteins are specifically sensitive to ataxia telangiectasia and Rad3-related protein (ATR) inhibitors. Replication stress activates DNA repair checkpoint proteins (ATR, CHK1), which prevent further DNA damage. This review describes the use of DNA repair checkpoint inhibitors as single agents and strategies combining these inhibitors with DNA-damaging compounds for ovarian cancer therapy, as well as the new platforms used for optimizing ovarian cancer therapy.Keywords
Funding Information
- Narodowe Centrum Nauki (2019/34/E/NZ7/00056)
This publication has 122 references indexed in Scilit:
- Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibitionCell Death & Disease, 2013
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesBritish Journal of Cancer, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Premature chromosome condensation induced by caffeine, 2-aminopurine, staurosporine and sodium metavanadate in S-phase arrested HeLa cells is associated with a decrease in Chk1 phosphorylation, formation of phospho-H2AX and minor cytoskeletal rearrangementsHistochemistry and Cell Biology, 2011
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian CarcinomaCancer Research, 2009
- Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2Current Opinion in Cell Biology, 2009
- Fine Tuning the Cell Cycle: Activation of the Cdk1 Inhibitory Phosphorylation Pathway during Mitotic ExitMolecular Biology of the Cell, 2009
- ATR: an essential regulator of genome integrityNature Reviews Molecular Cell Biology, 2008
- Chk1 and Claspin potentiate PCNA ubiquitinationGenes & Development, 2008
- Specific Role of Chk1 Phosphorylations in Cell Survival and Checkpoint ActivationMolecular and Cellular Biology, 2007